Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PFA-100 Evaluation and Reference Interval
NCT06100510Phase 4Enrolling by invitation
- Sponsor
- Hematology-Oncology Associates of Central New York
- Start
- Feb 2024
- Primary completion
- Oct 2024
- Countries
- 1
01
Overview
Phase 4, open-label trial (2 arms), sponsored by Hematology-Oncology Associates of Central New York. Primary endpoint: Platelet Function Analyzer-100 Aperture Closure Time at 3 months. Started Feb 2024; status: enrolling by invitation.
Beyond the preview
Go deeper on NCT06100510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06100510.